^
Association details:
| Biomarker: | PTEN underexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor) + Nubeqa (darolutamide) (Androgen receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
651 - Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models
Published date:
03/09/2022
Excerpt:
In the LuCaP 35 PDX model, which expresses PTEN at low level, darolutamide or copanlisib treatment alone showed only limited efficacy, while the combination exhibited tumor inhibitory effects. In conclusion, we found that combining darolutamide with copanlisib strongly inhibited the proliferation of prostate cancer models in vitro.
